To test the therapeutic benefit of neutralizing GCSF in the colorectal cancer model mice, AOM/DSS-treated mice were administered neutralizing anti-GCSF or isotype control (IgG1a) antibodies for 3 weeks, starting after recovery cycle 3 (Fig. 6A). Here, CSF3 is linked to colorectal cancer.